胎盘部位滋养细胞肿瘤与上皮样滋养细胞肿瘤:临床病理特征、预后变量与治疗策略
胎盘部位滋养细胞肿瘤(PSTT)和上皮样滋养细胞肿瘤(ETT)是最罕见的妊娠滋养细胞肿瘤,分别起源于植入部位和绒毛膜叶的中间型滋养细胞。两者生长缓慢、就诊时多为早期、βhCG水平相对较低且对化疗反应差,死亡率PSTT为6.5%至27%,ETT为10%至24.2%。晚期、前次妊娠至诊断间隔长及透明细胞是PSTT的独立预后变量,ETT可能相似;早期疾病可行子宫切除术,高危患者应辅助化疗,晚期需个体化多学科治疗,EP/EMA和TP/TE为首选方案。
要点
- PSTT和ETT罕见,死亡率分别为6.5%-27%和10%-24.2%。
- 晚期、前次妊娠间隔长、透明细胞是PSTT独立预后变量。
- 早期疾病子宫切除术可为唯一治疗,高危患者应辅助化疗。
核心结论
- PSTT和ETT罕见且对化疗反应差,早期可行子宫切除术,高危患者应辅助化疗,晚期需多学科个体化治疗,EP/EMA和TP/TE为首选方案。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- PSTT死亡率范围为6.5%至27%,ETT死亡率范围为10%至24.2%。
- 晚期、前次妊娠至诊断间隔长及透明细胞是PSTT的独立预后变量,ETT可能相似。
- 免疫组化有时显示EGFR、VEGF、MAPK、PDGF-R和PD-L1表达。
关键数值与推荐
- 早期疾病子宫切除术可为唯一治疗,辅助化疗应保留给具有不良风险因素的患者,如距前次妊娠间隔超过4年、深肌层浸润或浆膜受累。
- 晚期疾病首选EP/EMA和TP/TE方案。
- 年轻女性保留生育治疗的病例报告较少。
临床怎么用
- 早期PSTT和ETT可行子宫切除术,具有不良风险因素者应辅助化疗。
- 晚期疾病采用包括化疗和减瘤手术的个体化多学科方法。
- 化疗耐药疾病强烈需要针对EGFR、VEGF、MAPK、PDGF-R和PD-L1的生物制剂研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Placental site trophoblastic tumor [PSTT] and epithelioid trophoblastic tumor [ETT] are the rarest gestational trophoblastic neoplasias, developing from intermediate trophoblast of the implantation site and chorion leave, respectively. PSTT and ETT share some clinical-pathological features, such as slow growth rates, early stage at presentation, relatively low βhCG levels and poor response to chemotherapy. The mortality rate ranges from 6.5% to 27% for PSTT and from 10% to 24.2% for ETT. Advanced stage, long interval between antecedent pregnancy and diagnosis, and presence of clear cells are the independent prognostic variables for PSTT, and they may be similar for ETT. Hysterectomy can represent the only therapy for early disease, whereas adjuvant chemotherapy should be reserved to patients with poor risk factors, such as an interval from the antecedent pregnancy >4 years, deep myometrial invasion or serosal involvement. Few cases of fertility-sparing treatment in young women have been reported. An individualized multidisciplinary approach, including chemotherapy and debulking surgery with abdominal and/or extra-abdominal procedures, is warranted for advanced disease. EP/EMA and TP/TE are the preferred regimens in this setting. Immunohistochemistry has sometimes shown expression of EGFR, VEGF, MAPK, PDGF-R and PD-L1, and therefore investigational studies on biological agents targeting these molecules are strongly warranted for chemotherapy resistant-disease.
引用
- Gadducci A, Carinelli S, Guerrieri ME, et al. Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy. Gynecol Oncol. 2019. PMID: 31047719. doi:10.1016/j.ygyno.2019.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。